Member Info for crumbs

To read too much into Chippers words due to failure to get any commercial action yet but he did allude to todays RNS in the results.... much like SCIB2 action was alluded to before CRUK took it on... anyways maybe this new collab will lead to some commercial action... still waiting on BioNtech and TCR :)

Chippers:
'Our monoclonal antibodies and associated technologies are now firmly established as a third platform in the Scancell portfolio and we look forward to updating the market on the development of these assets in due course. '

' This technology offers a new opportunity for collaboration and commercial transactions with antibody engineering companies looking for differentiated therapeutic targets.'

I suppose as they do not want to be named.... not sure of reasons why but could be as it is a very competitive area and you do not want your rivals to know what you are up to so as to gain an advantage...I'm sure scancell would love to be able to name them!

'Scancell’s breakthrough is called AvidiMab, which works with monoclonal antibodies that already form the basis of some very effective targeted cancer treatments.

The mAbs being developed by the AIM-listed drug developer are different, however, to the run of the mill antibody.

That’s because they target tumor-associated glycans that are associated with malignancies. The ability to hone in on these so-called TaGs is enhanced with the use of AvidiMab.

Scancell has produced a pipeline of these next-generation antibodies for use in the collaboration process.'

I think 'next generation' pretty much explains scancell... ahead of the game ... and on all 3 platforms too... it will all fit one day... as we see as an example AZ gets into electroporation that is validated in a scancell trial just as scancell are leaving it behind (though stuck with it for current trial) :)

Article on today's news...

https://www.proactiveinvestors.co.uk/companies/news/902000/scancell-hails-first-antibody-collaboration-deal-902000.html

Well, obviously I expect that trial will be discussed too!... Just usually Lindy does her science talk last yea being Modi2's turn... I agree with frustration at lack of commercial but surely as pipeline advances the potential values only go up... if they are ever monetised that is :)

Probably will be the topic of Lindy's science session though... Revealing of this new platform and attached MaBs... Anyways not gonna be set sp alight news this but for me is more progress in right direction as it means there is interest in this newest of our platforms which now has a name too... pity we don't get to hear who is collaborating as that could have had an sp effect but means there is interest among the MaB players ... all positive that and what a pipeline! 3 platforms ...potential beyond cancer targets too ...poundland BioNtech... find any similar biotech with such a low mcap!!?

I seriously doubt this is an AGM appeasement move lol...

Indeed I like the word 'first' as it sounds like more to come... I think the MaBs platform is quite advanced as it has been created and developed by Lindy and team scancell science with Nottingham uni's NUTAC for many years

More progress... and a new platform name AvidiMab.... but who are the mysterious un named collaborators??

No, that's someone with money! :)

I expect early AGM is mostly about logistics of gathering all the worldwide dispersed BOD however maybe they all want to get together sooner than later for whatever reason/s ...anyways at least there is a trial running now! (I think )) And if Martin is there which I presume he will be as he seems quite proactive with his BOD position investments then it could be a fruitful affair ...hopefully a balanced Q&A too lol

It'll be interesting to see if any of Ichors other partners like AZ will run trials in the US with the new device Jansen the first to use it did not bother with FDA preferring Europe and now this scancell debacle must be off-putting to anyone thinking of using the Ichor in a trial in the US... A device whose development was funded by Pfizer no less :)...you watch though how nano delivery becomes the way in next few years... scancell once again ahead of the game... got to get us somewhere eventually surely!!

Another case of scancell punished for success KF wanted and indeed wants to run the trial FDA not playing ball is preventing that and there is no more time to waste enough of that has been wasted already...It would great to get a US arm running at some point but I'm not banking on it happening.... least the data will now flow

Cliff in answer to a question said it was due to end June

Yes, I see at least not at this stage any negatives to the Diggles being in and having real skin in the game too... An observation is John Glencross (calculus) has remained silent on them coming in or indeed on any recent scancell news on his twitter feed It would be interesting to know his thoughts and wonder has he spoken to Diggle since and possibly before him coming on board ( I presume so )

Well Chippers is underwater and will be feeling our pain :)...... unless of course, something is coming along to change that pre-AGM

There might be a particular resolution they want to get voted through by then...

Overslept

Our monoclonal antibodies and associated technologies are now firmly established as a third platform in the Scancell portfolio and we look forward to updating the market on the development of these assets in due course.

Sounds promising

Not just any ordinary mouse! Better not get into that though :)